Britain and America have reached a significant commercial pact that will maintain zero duties on UK drug shipments going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the NHS. This move guarantees that import taxes on these vital goods will remain at nothing for a timeframe of the next three years.
This deal is in response to previous statements to significantly raise duties on branded pharmaceutical products, with figures discussed up to 100%.
"This deal with the Britain reinforces the international landscape for cutting-edge drugs and brings much-needed balance to transatlantic medicine commerce," a release noted.
Trade Importance
Pharmaceuticals constitute one of the the United Kingdom's most significant goods shipped to the America, which is easily the largest market for leading British pharmaceutical firms.
Trade data show that in the 12 months to the end of September, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that period.
"This agreement secures employment, increases capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Specific British Pledges
The pact includes several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. Previously, refunds were more than twenty percent.
Broader Context
The deal takes place against a protracted tension between the drug companies and the ministers over spending levels and regulatory access.
The disagreement were exacerbated by claims that US patients were paying a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been announced toward US facilities.
The Science Minister acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had declined as a share of its resources over the past decade.
